Study of Bimekizumab Compared to Topical Corticosteroids for Treating Plaque Psoriasis in Adults Aged 18 to 45

What this Trial Is About

Psoriasis is a chronic inflammatory condition influenced by genetic and environmental factors, often leading to recurrent skin flare-ups. This trial evaluates the effectiveness of bimekizumab, a drug, compared to topical corticosteroids in managing psoriasis symptoms. The study aims to determine if early intervention with bimekizumab can delay the chronic inflammation typically seen in psoriasis over a 24-week period. Participants will be randomly assigned to one of two groups one group receives 320mg of bimekizumab at weeks 0, 4, 8, and 12, while the other uses clobetasol ointment daily for up to 4 weeks until the lesion clears. Afterward, clobetasol will be applied twice weekly until week 16, then stopped. No active treatment is given between weeks 16 and 24. From week 24 to 96, patients who experience flare-ups may use clobetasol continuously but will be classified as non-responders for main analysis. If psoriasis worsens to moderate or severe, participants leave the study for standard care. During the study, various assessments and sample collections will monitor the disease and treatment effects. Researchers will measure psoriasis activity using clinical tools at 24 weeks, focusing on skin condition and quality of life. Patients must attend all study visits and follow procedures, with the total participation period extending to up to 96 weeks depending on flare-ups and treatment response.

Early Intervention in Plaque Psoriasis: is Bimekizumab Able to Delay Chronic Inflammation?